American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation

Irritable bowel syndrome (IBS) and chronic idiopathic constipation ((CIC) also referred to as functional constipation) are two of the most common functional gastrointestinal disorders worldwide. IBS is a global problem, with anywhere from 5 to 15% of the general population experiencing symptoms that would satisfy a definition of IBS (1,2). In a systematic review on the global prevalence of IBS, Lovell and Ford (1) documented a pooled prevalence of 11% with all regions of the world suffering from this disorder at similar rates. Given its prevalence, the frequency of symptoms, and their associated debility for many patients and the fact that IBS typically occurs in younger adulthood, an important period for furthering education, embarking on careers, and/or raising families, the socioeconomic impact of IBS is considerable. These indirect medical costs are frequently compounded by the direct medical costs related to additional medical tests and the use of various medical and nonmedical remedies that may have limited impact. CIC is equally common; in another systematic review, Suares and Ford (3) reported a pooled prevalence of 14%, and also noted that constipation was more common in females, in older subjects, and those of lower socioeconomic status (3). Chronic constipation has also been linked to impaired quality of life (4), most notably among the elderly (5). Neither IBS nor CIC are associated with abnormal radiologic or endoscopic abnormalities, nor are they associated with a reliable biomarker; diagnosis currently rests entirely, therefore, on clinical grounds. Although a number of clinical definitions of both IBS and CIC have been proposed, the criteria developed through the Rome process, currently in its third iteration, have been those most widely employed in clinical trials and, therefore, most relevant to any review of the literature on the management of these disorders. According to Rome III, IBS is defined on the basis of the presence of: Recurrent abdominal pain or discomfort at least 3 days/month in the past 3 months associated with two or more of the following: Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form (appearance) of stool These criteria should be fulfilled for the past 3 months with symptom onset at least 6 months before diagnosis (6). Rome III defines functional constipation as: the presence of two or more of the following: Straining during at least 25% of defecations Lumpy or hard stools in at least 25% of defecations Sensation of incomplete evacuation for at least 25% of defecations Sensation of anorectal obstruction/blockage for at least 25% of defecations Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor) Fewer than three defecations per week Furthermore, loose stools are rarely present without the use of laxatives and there are insufficient criteria for IBS. Again, these criteria should be fulfilled for the past 3 months with symptom onset at least 6 months before diagnosis (6). In Rome III, IBS is subtyped according to predominant bowel habit as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), and unclassified (IBS-U). The definition of bowel habit type is, in turn, based on the patient’s description of stool form by referring to the Bristol Stool Scale (7). The recognition that IBS sufferers segregate into subtypes according to predominant bowel habit, together with research findings suggesting that IBS-C and IBS-D may be pathophysiologically distinct entities (8,9,10), led to the development of therapies specifically directed at each of these subtypes. Nonetheless, it is worth noting that symptoms may not be stable over a lifetime and individuals may exhibit one IBS subtype during a period, and then a different IBS subtype during another period in their lives. However, although there is general awareness of the Rome criteria, they are infrequently employed in the assessment of IBS and CIC in clinical practice (11). To provide more “clinician friendly” definitions, as well as to permit inclusion of studies that predated the Rome process, American College of Gastroenterology Task Forces suggested the following definitions in prior systematic reviews: IBS is defined by: abdominal discomfort associated with altered bowel habits (12). Constipation is defined as: a symptom-based disorder defined as unsatisfactory defecation and is characterized by infrequent stools, difficult stool passage, or both. Difficult stool passage includes straining, a sense of difficulty passing stool, incomplete evacuation, hard/lumpy stools, prolonged time to stool, or need for manual maneuvers to pass stool. CIC is defined as the presence of these symptoms for at least 3 months (13). It is important to note that the Rome III criteria state that individuals with chronic constipation do not fulfill criteria for IBS, with pain or discomfort being a major determinant in the latter. In practice, a clear separation between CIC and IBS with constipation may be challenging and studies have shown, not only considerable overlap between these entities (14,15,16), but also a significant tendency for patients to migrate between these diagnoses over time (15). It is appropriate therefore that in this update of prior American College of Gastroenterology monographs on IBS and CIC, these entities be addressed in the same exercise (12,13,17). The goal of this exercise, therefore, was to update the most recent systematic reviews commissioned by the American College of Gastroenterology on IBS from 2009 (17) and CIC from 2005 (13). have a of systematic reviews on the of in IBS and have been systematic reviews of for IBS and CIC in the past 5 have been considerable in the and therefore, all these systematic reviews of IBS and CIC and the the from The of this exercise was to the of therapies in IBS and CIC with or The the of therapies in IBS according to predominant stool reported with IBS with and mixed as well as with therapies for both IBS and review that any definition of IBS or IBS, this a the criteria the or Rome or III CIC, this symptoms by any of the Rome criteria as well as a only trials with or trials for at the of the period, before IBS, the following and that the CIC, the following and laxatives to be for at least To be trials to one or more of the following assessment of in IBS or CIC symptoms Improvement in abdominal pain for IBS IBS symptom or abdominal pain for IBS number of stools per week during for CIC for of studies to and to and the of trials on IBS with the bowel syndrome and functional as medical and and IBS, and functional bowel of these the with studies with the or as and or the following or of and these the with studies with the or as and or the following or of these the with studies with the or as and of and these the with studies with the and or and of these the with studies with the or as and or the following or of these the with studies with the or as and or the following or of and these the with studies with the or as and or the following or of these the with studies with the or as and or the following or of these the with studies with the following or of these the with studies with the as a and on CIC with the constipation or gastrointestinal as and or functional idiopathic chronic or the the pelvic and also of these the with studies with the or as and or the following or of and these the with studies with the as and or the following of and of these the with studies with the or as and or the following or of these the with studies with the following or of these the with studies with the and and the following or of these the with studies with the following or of these the with studies with the or as and of and these the with studies with the and or and The was limited to with to of of the of relevant was also and Gastroenterology between and of that not for and to in the for on for of according to the in the the following to the to of of and of an and by the and by a on to developed was by between the two in to a as all to be IBS, any of global IBS symptoms as a was as the this was not in abdominal pain was CIC, any of global CIC symptoms as a was as the The impact of was as a of IBS or CIC symptoms not together with there the and to a more of the of IBS as global IBS symptom or IBS symptom a with was It should be noted that may be in IBS or CIC of the on than global symptoms or abdominal but this was not and was of the of this of reported the of was significant and/or the for this by in or in or of tests for studies The number to is the number of patients would need to over and the for one to an in symptoms, and the number to is the number of patients would need to over and the for one to an as the of the from the and the is and is for of and the of and for the quality of and of for each medical The has been widely in and is by all major gastrointestinal The quality of the is based on the as well as the of of and that for the the of is as to on the to would change the of The also as or according to the quality of the to all of and and this the or not should be to most and or not are to change in the of a that to most patients in most and is to change in the of The of the for IBS is in the for the on the quality of that in and the for the of in the of the for CIC is in the for the on quality of the in and the for the of in of the of the quality of of of on for for quality of of assessment for IBS according to for of for IBS therapies according to of of on for for quality of of assessment of on CIC according to for of for of CIC according to Irritable bowel syndrome and in IBS of in Although is one of the most common of symptoms in IBS to and with of the have not typically in the of a on their IBS sufferers have their to this or from IBS patients that they have an to although are in IBS although the prevalence of in is between and in of gastrointestinal patients that that their symptoms or IBS symptoms to although only of patients the in a on their with and a of to a studies have that a of IBS patients to an that may their of in may symptoms in IBS of that in IBS to of relevant symptom and an week three patients The of these addressed the impact of in IBS. In a patients with IBS to on a or to of on of an In the reported that their symptoms not as with in the symptom for abdominal with stool and in those a The of these studies the of or as not by but by In a IBS patients to an based on the presence of to various or a for and symptoms a global impact and the IBS with in the in the noted a significant in The reported in those with to their The third the of and IBS patients to a or their for those to the reported of their symptoms with of the Stool not between stool frequency was in the significant of this was the of the the of in the of symptoms, or in the of IBS, is being To two and have been addressed in clinical although it is that (e.g., of and with the may also be relevant to the of or the that any of the of an or of a in IBS the provide limited on the of in the management of IBS. and but their in the management of IBS need to be in IBS symptom in IBS. of but not symptom in IBS. of of is frequently to bowel for IBS, for However, frequently and abdominal In prior systematic review two additional studies for a of but trials not IBS by subtype and only two to IBS-C In the to of IBS-C and to one of three of the of the or of a for the a of patients but not reported symptom for at least with was more than during the third of only 3 months of symptom in the was by with in the and in the with to quality of was most common in the most of in IBS. on only by trials These trials but as of in 5 of the of was not of of patients reported with of in the Although its use in the management of IBS is time the status of in in IBS, is from may symptoms and provide and in provide in IBS. These to in of of that the and The that the be relevant to IBS from the that a although of individuals an of on to IBS IBS Although has been linked to and and in the have been in IBS, the of the to or symptoms in IBS, is although both and and in the have also been linked to IBS the of to IBS and findings in to the in and have been for on an basis by IBS they have only been to in clinical The of studies in IBS challenging as studies have employed different and in various and in Although the suggested that more than of all IBS sufferers studies in to a prevalence of in IBS These may to to the that may provide an of the this a for in IBS. a has in clinical trials in and although significant over in global IBS symptoms as well as in it is important to note that tests for not in these the of of in IBS and in is insufficient to or in IBS. of in as a global symptoms, and in IBS. or be at this time of insufficient and of in is at IBS symptoms and in IBS. of one that the in IBS this was from as the not In to it should be noted that in and of on these are addressed in two trials IBS patients that studies different two of in IBS as not in one and in the there was was one that in patients of patients to with symptoms with of to trials global IBS symptoms on a in there was significant of in IBS symptom both trials of significant systematic review and on in IBS and a of trials However, one of these was a of a in the in form and one in the was and in both and these two studies in there trials at of with the being patients reported on that as a than of IBS not with the of was significant between in the assessment of was the use of a of as well as based on widely and in only a significant for and but there was significant between studies for the two and only one for the and patients reported in global IBS symptom or abdominal pain was a significant of in symptoms with significant on this significant for of but not for those or and that reported the of on symptom with but with significant between In the trials that this lower with with with significant was for on in the trials that this reported by of patients to any with of to with the of 6 that in IBS trials and as they not provide but was as it symptoms a of IBS symptoms with with significant between in patients with a significant in of with the of 5 The 5 trials in IBS was a significant in of the with the of three of trials reported in was in between the and of Although to a for the in IBS, the of any reported in in the of IBS to be at this time there is insufficient to permit a on the use of or in IBS, do a for with and to be the that between and the to on to as well as a of to a or at this The although not for this by the and has but in IBS and to be well and, the or use of an has at least over the time in it has been in IBS have been for on an basis in the of IBS based on the that and to IBS symptoms and pain in the and provide in IBS. are more common with than of patients with IBS. was considerable between the studies and inclusion criteria, and 3 studies criteria or all studies IBS, the fact that most trials before Rome definitions The of trials not between the of IBS patients the quality of trials was with only more than trials reported an of and reported on of although all of was in all of the the in the various only and are in the review that as a has a significant in IBS symptoms with the of 5 However, the of is and difficult to as there are only a number of studies each of the different for to and with of and However, of these in as as one and for those that in was a in and not have a significant on IBS symptoms, although the of patients trials in this review reported with or In of patients to with of to the of was among those as with of experiencing any with the of The most common and but there reported in in any of the Although many of the relevant clinical trials are and from in of as a are in IBS, their use may be limited by However, not all have been to be and studies on in quality and Furthermore, the of of the more may be limited to in IBS be in various through or that it but it may also have of and of pain and its use for the of IBS. is to in IBS The of is with than with of trials not between the of IBS patients with only one on this was only one at of with the being reported a of on IBS symptoms with but this was there was a significant in of with with the of 3 However, there was significant between In these an of was employed in from to the of was not among those as with of experiencing any In may not be is in IBS. in IBS is insufficient to for use in IBS. of two was significant in of with trials the type of IBS patients with one only patients and the only IBS-D on in both in in one and in each of the Although is an there is to support the use of for of global symptoms in IBS. in IBS into the management of IBS based on the that and among IBS in and studies suggested that in these in pain of and are in symptom in IBS. are common and may of systematic review and on in IBS and there The of trials not between the type of IBS patients with studies on this one of only IBS-C patients and another only IBS-D patients three of the at of with the being in IBS symptoms with the of The of on abdominal pain was reported by with of patients abdominal pain following as with of to a of abdominal pain of but with considerable between studies in patients and was associated with a in IBS symptoms with with the of in patients and was associated with a in IBS symptoms with with the of trials reported on In of patients to as with of to the of was among those as with of experiencing any The was and more common in patients than those on and are in global symptom and pain in IBS. and as well as have limited their use and than (e.g., of do not permit on for in IBS of are in IBS of systematic review and on therapies in IBS and a of in patients The quality of these trials was with only a of more than of the of the studies would not have been but only reported that of the trials at of was a significant in of therapies with the of but with significant between In of the different of therapies the for of 3 of of the of 5 and of significant for the or However, the three have only been in one or two and therefore a of be trials or as a reported by any Although to and of have their a of the have been to be in IBS. of in the management of IBS their a in gastrointestinal and and a of have been for development in functional gastrointestinal disorders The subtype 3 have been to an important in and from the and a was therefore in IBS and, although it of constipation and to its by the and It was by the in a a management for suffering with IBS that is The management was to a and in as and have been into clinical The subtype are the gastrointestinal and of these the and gastrointestinal is an as a The for the use of in with IBS with constipation in of was from the in is the only that has been in studies in IBS is in the an of and has not been The is referred to the systematic review number of have been developed and have in constipation (e.g., that is in and the but as on the or of these for the of IBS. in is in with IBS. of systematic review and and two studies a of trials patients for inclusion one was at of with the but one IBS. trials or with the of two studies and a that only there was a significant in of with the of and significant to be in between the three and this all with of and studies patients that more than of any The was The that was more common with than with was has been reported with and it was by the in In the the of a that of to only with IBS. The includes a management a and to patients and are of the and of in of these was as there and has been in most are not more than at symptoms of IBS. of The in the of IBS symptoms is to an of and as mixed have been developed for the of IBS. These are and It should be noted that has not been widely from the in and that this was to be not more than in a recent of trials patients for inclusion studies each or one trials patients with IBS and one mixed IBS The quality of trials was of all studies significant between and mixed for the of IBS and significant was between In of in or mixed IBS nor significant over was significant in with mixed as with the various and to that have been developed and in IBS, only and both are in regions and by of of the use of in the is limited to with IBS and be only in the of a is for the management of IBS in and is to for the of IBS. of is a similar to in the are that in the of and by and on the of of in an of that a of to the of the that in of and into the by and into the as well as of pain clinical trials in IBS patients patients trials at of and there was significant between was a significant in of with with the of 6 with significant between was a significant in of with on abdominal pain of but with significant between on by two of the three trials not among those with However, reported in all three was more with as with with the of 6 reported in two trials was also more common with with the of is to for the of IBS. of the type on the of the in and into the in through the and clinical trials of in IBS patients have been reported in three However, one of these was a mixed population of IBS and CIC patients studies reported in IBS patients trials at of was a significant in of as with with the of and significant between the three The quality of was as according to criteria, as the on IBS symptoms was and the for the was to a Furthermore, for IBS patients from one not on reported in all three but pooled for the two trials reported in a In the by reported by of patients as with of but this was not was also with with with but this was not The only more frequently among those was diarrhea In the two studies that pooled and of IBS patients and reported at least one in of patients with of those was reported by of those to with of those to The and are in IBS. both of these in with than their in an IBS for those have or as is difficult to and by of on should be in IBS, the of on in IBS is that symptoms and pain in patients with IBS. of is a that as an and although it is by the for the of it has not been in patients with in with IBS-C suggested that stool frequency but not pain only two of in IBS. In one there was significant on bowel or discomfort and pain In the patients with IBS with the in bowel was with with at but there was in on abdominal pain or defined as more than bowel per week with an of two or more from and of abdominal pain or with with However, there was significant in the of patients with a pain defined as a by or more from with but most of these or is that pain or provide symptom in IBS. Chronic idiopathic constipation in CIC and stool frequency in patients with chronic idiopathic of is defined as that are of being in the and are to the be of or and as a is as or on its with is the is is the of the in as from the It in the and to and studies have been with in CIC and the quality of the use of these is trials the criteria for inclusion in this review but a was only with three trials and the studies not be of or a to provide for with the was of the trials three and the a of and in one and in the from the three trials suggested that was with with the of and significant between Although these trials be for the definitions of all and in one not all patients in the the that was to present at The in this therefore to be with In of among the three trials that the by although between these all reported significant with of a of and as a and reported significant in the of patients with during of incomplete evacuation, or of with In the number of between bowel was also trials reported on the of in CIC The patients to of per or significant noted with but was reported reported the number of patients in each of with and two with with of patients experiencing abdominal pain with of but in or there symptom for gastrointestinal as abdominal and with with and in are in the management of chronic and

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.